Mutations in KRAS are among the most frequent oncogenic events in human cancer and occur in roughly 30% of lung adenocarcinomas. The mechanisms by which KRAS‑mutant lung tumours avoid apoptosis driven by oncogenic stress remain incompletely defined. This study identifies the anti‑apoptotic regulator FLIP (CFLAR) as a critical survival dependency in KRAS‑mutant lung cancer and characterises the underlying mechanism linking KRAS signalling to caspase‑8 regulation.
The authors report that human lung cancer cell lines harbouring oncogenic KRAS exhibit elevated FLIP expression relative to KRAS wild‑type counterparts. These KRAS‑mutant cells show an enhanced reliance on FLIP for viability, indicating a selective dependency that correlates with KRAS mutation status.
Using genetically engineered mouse models (GEMMs) of Kras‑driven lung cancer, the study demonstrates that FLIP is essential for tumour development in vivo. Loss of FLIP impaired Kras‑driven lung tumour formation in these models, supporting a requirement for FLIP during oncogenic KRAS‑mediated tumorigenesis.
In vitro, FLIP‑deficient lung cancer cells undergo spontaneous apoptosis that is caspase‑8‑dependent. These FLIP‑null cells are hyper‑sensitive to the immune and inflammatory cytokines TNFα and TRAIL, exhibiting increased apoptotic responses when exposed to these ligands. Thus, FLIP functions to block caspase‑8 activation and prevent cytokine‑triggered cell death in KRAS‑mutant lung cancer cells.
Functional experiments indicate that silencing of TNFR1 or TNFα rescues the constitutive caspase‑8 activation and apoptosis observed in FLIP‑null lung cancer cells. In contrast, silencing TRAIL‑R2 did not provide rescue. These results implicate the TNFα/TNFR1 axis as the primary mediator of the apoptotic response following FLIP loss in this context.
Mechanistic studies within the report show that oncogenic KRAS maintains FLIP expression through ERK1/2 signalling. Sustained ERK1/2 activity downstream of mutant KRAS keeps FLIP levels high, thereby protecting tumour cells from caspase‑8 activation and apoptosis. This establishes a KRAS–ERK–FLIP signalling axis in KRAS‑mutant lung cancer.
Importantly, inhibition of KRAS reduced FLIP expression and increased cell sensitivity to TNFα‑ and TRAIL‑induced apoptosis. These findings provide a mechanistic explanation for pro‑apoptotic effects observed with KRAS inhibition and suggest a potential combinatorial vulnerability when targeting KRAS or its downstream signalling.
The results identify FLIP as a promising therapeutic target in KRAS‑mutant lung cancer. Because KRAS signalling sustains FLIP and FLIP loss unmasks sensitivity to TNFα/TNFR1‑mediated apoptosis, targeting FLIP directly or indirectly via KRAS/ERK inhibition could increase tumour cell death. The authors also suggest that tumour FLIP expression may serve as a predictive biomarker to stratify patients and potentially enhance the clinical efficacy of KRAS inhibitors in lung cancer.
These data are reported in a preprint that has not undergone peer review. Specific experimental details, such as cohort sizes, statistical metrics, dosing regimens, and potential toxicities, are not reported in this summary and should be consulted directly in the preprint for full methodological information. Funders declared include the Medical Research Council, BBSRC, Wellcome Trust, and Cancer Research UK.
Collectively, the study provides evidence that oncogenic KRAS enforces expression of the anti‑apoptotic protein FLIP via ERK1/2, enabling KRAS‑mutant lung tumours to evade caspase‑8‑dependent apoptosis. Loss of FLIP exposes a vulnerability mediated primarily by the TNFα/TNFR1 pathway and prevents tumour engraftment in models that retain TNFα‑expressing myeloid cells. These findings nominate FLIP as a survival factor co‑opted by KRAS‑mutant lung cancers and support further investigation of FLIP as a therapeutic target and biomarker in this disease setting.